This inventor holds 3 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Ip2ipo Innovations Limited, Id Pharma Co., Ltd., Isis Innovation Limited. Active years: 2014-2022.
Company Filing History:
2 out of 52 
1 out of 9 
1 out of 330 Years Active: 2014-2022
Title: Deborah Gill: Innovator in Gene Therapy
Introduction
Deborah Gill is a prominent inventor based in Oxford, GB. She has made significant contributions to the field of gene therapy, particularly through her innovative patents. With a total of 3 patents, her work focuses on advancing medical treatments for various diseases.
Latest Patents
One of her latest patents is a nucleic acid construct that provides a promoter for high-level and sustained expression. This construct can be utilized for gene expression of selected sequences. Specifically, it includes a hCEF1 promoter operably linked to a sequence for expression, which comprises a human CMV enhancer linked to a human EFI a promoter. Another notable patent involves lentiviral vectors, which are gene transfer vectors pseudotyped with hemagglutinin-neuraminidase and fusion proteins from a respiratory paramyxovirus. These vectors are designed for gene therapy, particularly targeting respiratory tract diseases such as Cystic Fibrosis.
Career Highlights
Throughout her career, Deborah has worked with notable companies, including Ip2ipo Innovations Limited and Isis Innovation Limited. Her expertise in gene therapy has positioned her as a key figure in the development of innovative medical solutions.
Collaborations
Deborah has collaborated with esteemed colleagues such as Stephen Hyde and Eric Walter Frederick Wolfgang Alton. These partnerships have further enhanced her research and contributions to the field.
Conclusion
Deborah Gill's work in gene therapy exemplifies her commitment to innovation and improving healthcare outcomes. Her patents reflect her dedication to advancing medical science and providing solutions for challenging diseases.